Big Pharma Reacts to Russia's Move on Ukraine
Big Pharma Reacts to Russia's Move on Ukraine
Attachment: Map
May 25, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--While promising to keep the availability of essential drugs needed by Russian citizens, major drug companies have responded to the Ukraine invasion from a financial position. The responses all seem to center on cancelling or halting planned capital investments, along with discontinuation of clinical trials in Russia. Nobody currently in a clinical trial will be abandoned, but no new studies will be started.
Companies featured: Pfizer Incorporated, (NYSE:PFE) (New York, New York), Novartis International AG (NYSE:NVS), Novo Nordisk A/S (NYSE:NVO), Eli Lilly (NYSE:LLY)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Novartis Sells Landmark Grimsby API Plant to Site Developer IPP
- Novartis To Make Pfizer/BioNTech COVID-19 Vaccine in Slovenia
- Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal
- Russia Taps Italy to Manufacture Sputnik V COVID-19 Vaccine
- Novartis Investing Big in Austrian Generics Plant